Neurogene FY2025 net loss rose 20.3% to USD 90 million

Neurogene Inc. -1.11% Pre

Neurogene Inc.

NGNE

21.37

21.37

-1.11%

0.00% Pre
  • Neurogene published a press release reporting full-year 2025 financial results and recent business updates.
  • Net loss was USD 90.4 million, while research and development expenses rose 23.2% to USD 75.0 million.
  • General and administrative expenses increased 25.2% to USD 28.3 million, driven by higher employee-related costs including non-cash stock-based compensation and headcount.
  • Cash, cash equivalents and short-term investments totaled USD 269.0 million, with the company expecting this to fund operations through the first quarter of 2028.
  • Rachel McMinn said enrollment is complete in the Embolden registrational trial for NGN-401 and the company remains on track to complete dosing in the second quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603240730BIZWIRE_USPR_____20260324_BW872399) on March 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.